A study of 142,000 patients suggests GLP-1 medications may influence brain pathways involved in cravings for nicotine, opioids, and alcohol.
RT’s Three Key Takeaways:
- Reduced Addiction Risk: Patients taking GLP-1 medications showed significantly lower rates of developing alcohol, nicotine, opioid, and cocaine use disorders compared to those not on the drugs.
- Neurological Influence: Researchers believe these medications may affect dopamine signaling and reward pathways in the brain, which could reduce cravings for substances beyond food.
- Clinical Trial Necessity: While the observational data is promising, the study authors emphasize that randomized clinical trials are required before these medications can be recommended for addiction treatment.
Researchers at the University of Texas at El Paso (UTEP) found that the use of weight loss and diabetes medications is associated with a lower risk of developing alcohol, opioid, nicotine, and cocaine use disorders, according to a study published in Frontiers in Psychiatry.
The study, led by UTEP school of pharmacy researchers Tadesse Abegaz, PhD, and Gabriel Frietze, PhD, examined more than 142,000 cases of patients with type 2 diabetes or obesity. Of those patients, approximately 20,000 were prescribed glucagon-like peptide-1 (GLP-1) medications. The research team analyzed whether GLP-1 users were more or less likely to develop substance use disorders than similar counterparts who were not on the medications.
According to the findings, patients taking GLP-1 medications had a 50% lower rate of alcohol use disorder and a 40% lower rate of nicotine use disorder. The study also observed lower rates of opioid and cocaine use disorders among these patients.
GLP-1s were originally developed for treating obesity and diabetes, but emerging evidence suggests these medications may influence dopamine signaling and other neural pathways that contribute to cravings for various substances.
“Our findings add to growing evidence that GLP-1 medications may influence more than appetite and blood sugar regulation,” said Abegaz, lead author. “These medications appear to affect brain pathways involved in reward and craving, which could help explain the lower rates of substance use disorders observed in our study.”
The research team emphasized that the findings are observational and do not establish a cause-and-effect relationship, noting that GLP-1s do not specifically prevent patients from abusing substances.
“We do not support prescribing these medications for addiction treatment at this time,” said Frietze, researcher, in a news release. “Because this was an observational study in a specific clinical population, randomized clinical trials are needed before GLP-1 medications can be recommended for treating addiction.”
The study utilized patient data from the National Institutes of Health (NIH) All of Us Research program. The researchers plan to conduct prospective research to follow individuals initiating GLP-1 therapy over time to evaluate whether changes in substance use behaviors occur after treatment begins.
“Ultimately, this work will help inform whether GLP-1 medications could become part of future treatment strategies for substance use disorders,” said Abegaz.
